A side-by-side comparison to help you understand your options
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
There is no single "best" treatment for squamous cell carcinoma (SCC) — the right approach depends on the tumor's size, location, depth, and risk features, along with your own health and preferences. What works well for a small, low-risk SCC on the forearm may be entirely wrong for a larger, high-risk tumor near the eye or ear.
This guide compares the main treatment options honestly — cure rates, cosmetic outcome, recovery time, and when each one is and isn't appropriate — so you can have an informed conversation with your dermatologist or Mohs surgeon about which path fits your specific tumor. If you're still working out how your particular SCC was classified, our guide to staging and grading explains how that classification shapes the recommendations below.
Surgery cures the large majority of SCCs, but the two most common surgical approaches differ significantly in how the margins are checked and where each is best suited.
Considered the gold standard for high-risk SCC and for tumors in cosmetically sensitive or tissue-sparing areas — the face, ears, nose, lips, hands, and genitals. The surgeon removes the tumor in thin layers, examining 100% of the surgical margin under a microscope in real time before closing the wound, rather than checking a small sample after the fact.
Pros: the highest reported cure rates (roughly 95-99% for primary tumors), the most tissue-sparing option since only cancerous tissue is removed, and same-day margin confirmation.
Cons: requires a specially trained Mohs surgeon, appointments can take several hours as layers are processed, and it isn't necessary — or typically covered as first-line — for small, low-risk tumors that standard excision handles just as well.
The tumor is cut out along with a margin of visibly normal skin around it — a 4-6mm margin is the standard recommendation for well-defined, low-risk SCCs under 2cm, per NCCN guidelines, with wider margins recommended for higher-risk tumors. The tissue is then sent to a lab for margin analysis, with results typically available in several days.
Pros: faster in the office than Mohs, widely available from general dermatologists and surgeons, and excellent cure rates for appropriately selected low-risk tumors.
Cons: only a fraction of the margin is actually examined (unlike Mohs' complete margin check), so there's a small chance the pathology later shows a positive margin requiring a second procedure; also removes more healthy tissue than Mohs to achieve the same margin, which matters more in cosmetically sensitive areas.
This technique scrapes away the visible tumor with a curette, then uses an electric current to destroy any remaining cancer cells and control bleeding — often repeated for two or three cycles in the same visit. It's fast, doesn't require stitches, and can be done in a standard office visit.
Pros: quick, low cost, no suturing, and good cosmetic results on the trunk and limbs for the right tumor.
Cons and important limits: this method should only be used for select low-risk, superficial SCCs on the trunk or extremities. It is not appropriate for tumors with high-risk features — on the face, ears, scalp, hands, feet, or genitals; larger than 2cm; recurrent; poorly differentiated; or with perineural invasion — because the tissue isn't examined under a microscope, so there's no way to confirm the margins are actually clear. Using it on a high-risk tumor raises the chance the cancer isn't fully removed.
Radiation uses targeted energy delivered over a series of sessions (often several weeks) to destroy cancer cells. It has two main roles in SCC treatment: as a primary treatment for patients who aren't good surgical candidates — due to age, other medical conditions, tumor location, or personal preference — and as an adjuvant treatment after surgery, most often when the pathology shows a positive or close margin, or evidence of perineural invasion, that raises the risk of leftover microscopic disease.
Pros: avoids surgery and its recovery entirely when used as primary treatment; as an adjuvant treatment, meaningfully lowers local recurrence risk after surgery for high-risk features.
Cons: requires multiple visits over several weeks rather than a single procedure, cure rates as a stand-alone treatment are generally somewhat lower than surgery for equivalent tumors, and it carries its own long-term skin changes at the treatment site (thinning, discoloration, or telangiectasias) that develop over months to years.
A small minority of SCCs grow too large, invade too deeply, or spread to lymph nodes or distant organs to be managed with surgery or radiation alone. For these cases, systemic treatment has changed dramatically over the past decade. See our guide on recurrence and metastasis risk for the features that make a tumor more likely to reach this stage.
Cemiplimab and pembrolizumab, both PD-1 checkpoint inhibitors, are now the first-line systemic treatment for locally advanced or metastatic cutaneous SCC that isn't curable with surgery or radiation. In the pivotal trial that led to cemiplimab's approval, about 47% of patients with advanced disease had a measurable response, with many responses proving durable. Pros: meaningfully better response rates and generally more tolerable side-effect profile than older chemotherapy. Cons: can cause immune-related side effects affecting the skin, gut, lungs, or hormone glands, and not every patient responds.
Before immunotherapy became available, EGFR inhibitors (such as cetuximab) and platinum-based chemotherapy were the standard options for advanced SCC, and they're still used today for patients who can't tolerate or don't respond to immunotherapy. Pros: long track record and an option when immunotherapy isn't suitable. Cons: generally lower response rates and more difficult side effects (including significant fatigue, skin reactions, and blood count suppression) than current PD-1 inhibitors, which is why they've moved to a second-line role for most patients.
Most SCCs — especially when caught early — are cured with a single, relatively straightforward surgical procedure. The choice between Mohs surgery, standard excision, and less common options like curettage and electrodesiccation comes down to the tumor's risk features and location, not which one is universally "better." Radiation and systemic therapy exist as important options for the smaller group of patients for whom surgery alone isn't the right fit.
Whatever treatment you and your doctor choose, understanding the trade-offs — cure rate, cosmetic outcome, and recovery — helps you feel confident in the plan rather than simply following a recommendation you don't fully understand. Once treatment is complete, our guide to follow-up care after SCC treatment covers what surveillance looks like next.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Treatment decisions depend on your specific tumor and health history — always consult a qualified dermatologist or oncologist about which option is right for you.
Chat with our AI guide for personalized information about SCC treatment options
Chat with the Navigator